Mobile

PHASE 4, PROSPECTIVE, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE SMOKING CESSATION WITH VARENICLINE TARTRATE COMPARED WITH PLACEBO IN THE SETTING OF PATIENT SELF-S...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-001497-33

PHASE 4, PROSPECTIVE, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY TO EVALUATE SMOKING CESSATION WITH VARENICLINE TARTRATE COMPARED WITH PLACEBO IN THE SETTING OF PATIENT SELF-SELECTED (FLEXIBLE) QUIT DATE

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary efficacy objective of this protocol is to compare 12 weeks of treatment with varenicline 1 mg BID to placebo for smoking cessation in the setting of a patient selfselected quit date (before Week 5 visit), and to evaluate continuous abstinence from smoking for 12 weeks after the treatment period.

Critère d'inclusion

  • SMOKING CESSATION

Liens